<DOC>
	<DOC>NCT02274376</DOC>
	<brief_summary>This observational study will collect prospective data on the safety and tolerability of Xeloda in patients with advanced gastric cancer from every day clinical practice. Documentation of treatment for each patient is to continue until the end of treatment per oncologist's assessment.</brief_summary>
	<brief_title>Non-Interventional Study of Xeloda (Capecitabine) in Patients With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Patients aged &gt;/=18 years, with metastatic gastric cancer who are available for prospective documentation of their treatment (firstline chemotherapy) Informed consent Contraindications to Xeloda per the Summary of Product Characteristics (SmPC)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>